CHRS
Tagmokitug shows high response rates in esophageal cancer
Coherus Oncology announced impressive interim clinical data for tagmokitug in esophageal cancers, supporting further development of the therapy for hard-to-treat cancers.
CHRS news
Latest 5 stories · newest Oct 29, 2026
CHRS
Coherus Announces Special Cyber Dividend of CVRs
Coherus Oncology (CHRS) will distribute a special dividend of contingent value rights to stockholders, entitling them to the net proceeds from the sale of remaining legacy biosimilar assets. This restructuring measure underscores the company’s strategic pivot to focus exclusively on innovative immun…
CHRS
Coherus enters loan agreement
Coherus Oncology, Inc. has entered into a loan and security agreement, as amended an exhibit to an 8-K filing.
CHRS
Coherus CSV revenue up 15% as pipeline studies advance
Coherus reports LOQTORZI revenue of $13.6 million for Q2 2026. Clinical data continues to mature across programs, with preliminary evidence of activity featuring a new cancer asset.
CHRS
Coherus Oncology auditor Ernst & Young agrees with Item 4.01 disclosure
Ernst & Young LLP confirmed agreement with statements in Coherus Oncology's Form 8-K Item 4.01 filing dated June 12, 2026, regarding an auditor change. The filing indicates a transition in the company's external audit relationship.
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.
The same CHRS feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/CHRS/newsSTART FREE